Enanta Pharma loses appeal in Pfizer Paxlovid patent case

Enanta Pharmaceuticals (NASDAQ: ENTA) lost its patent infringement appeal against Pfizer Inc. after the United States Court of Appeals for the Federal Circuit ruled on June 23, 2026, that the claims of U.S. Patent No. 11,358,953 were invalid.

The Federal Circuit's decision affirmed a December 2024 summary judgment ruling by the United States District Court for the District of Massachusetts. Enanta had filed the appeal seeking damages for alleged infringement related to the manufacture, use, and sale of Pfizer's COVID-19 antiviral Paxlovid (nirmatrelvir tablets; ritonavir tablets).

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Netflix raises $1 billion in senior notes due 2036
• GE Aerospace and Magellan sign F414 engine MRO deal for Canada